Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
News|Articles|September 2, 2002
- Pharmaceutical Technology-09-02-2002
- Volume 26
- Issue 9
An Overview of the Validation Approach for Moist Heat Sterilization, Part I
Author(s)E. Pretorius, PhD
Part I of this article discusses examples for cycle types used in moist heat sterilization, parameter requirements for a standard cycle as defined by pharmacopeias, methods used to design sterilization cycles, and various approaches used to measure the efficiency of the sterilization process.
Advertisement
Articles in this issue
about 24 years ago
Innovations of Membrane Chromatography for Biomolecular Purificationabout 24 years ago
New Syringe Designs Combine Prefilled Convenience with Safetyabout 24 years ago
Outsourcing Outlookabout 24 years ago
Spreading of Semisolid Formulations: An Updateabout 24 years ago
Auditing Your Contractorabout 24 years ago
Attack Mounts on Drug PricesAdvertisement
Related to this article
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
Formulation Strategies for Next-Generation Multiagonists
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
First-in-Human Trial Speed: Why FDA Trails China
5